The project was conducted by Truly Labs for a global pharmaceutical client, where Lumito’s SCIZYS platform was used to analyse rare cells in complex tissue samples. The project has now been completed with successful results, and Truly Labs has invoiced its end customer. In connection with this, Lumito is invoicing Truly Labs for reagent kits and Scan-as-a-Service. The order value for Lumito amounts to approximately SEK 30,000.

The project builds on results in the detection and quantification of so-called “rare” cells, communicated in a press release on December 18, 2025, and represents a further example of how the SCIZYS platform can add value in advanced tissue analysis.

“It is very positive to see that our partnership with Truly Labs is now generating revenue. Although this is a single project, it represents an important initial confirmation that our strategy of working through CRO partners can create both business opportunities, increased visibility, and additional evidence for our technology,” says Sanna Wallenborg, CEO of Lumito.

The collaboration between Lumito and Truly Labs began in December 2024 and has since developed step by step, from pilot studies to the integration of SCIZYS into Truly Labs’ customer offering. The current project represents a concrete commercial outcome of this collaboration.

“Truly Labs is a CRO where we continuously challenge ourselves to find the best way to support our customers. The collaboration with Lumito has, through SCIZYS, provided us with an exciting new tool to generate high-quality data for customer projects, even when the research questions are new and challenging,” says Karin von Wachenfeldt, CEO of Truly Labs.

The project has been completed according to plan. The work has confirmed the strength of Lumito’s collaboration model with CRO companies and demonstrated that the platform can effectively reach pharmaceutical and research customers, thereby strengthening the Company’s continued commercialisation efforts.